)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Biostem Technologies
Biostem Technologies (BSEM) investor relations material
Biostem Technologies Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary2 Oct, 2026
Company overview and business model
Develops and commercializes placenta- and umbilical-cord-derived allografts for advanced wound care and surgical use; products span dry, cryopreserved, and shelf-stable formats.
Proprietary processing platforms are BioRetain, CryoTek, and SteriTek; portfolio includes Vendaje, Neox, Clarix, and other tissue products.
January 2026 BioTissue asset acquisition added Neox and Clarix, sales infrastructure, and GPO/IDN relationships; manufacturing transfer may begin as early as 12 months after acquisition.
Strategy centers on expanding into hospitals and ASCs, broadening products, scaling direct and independent sales, and moving acquired manufacturing in-house to improve supply efficiency and margins over time.
Financial performance and metrics
FY2025 revenue was $47.48m vs. $69.66m in FY2024; net loss was $6.58m vs. net income of $31.03m.
H1 2026 revenue was $14.03m vs. $26.93m in H1 2025; net loss was $17.79m vs. net income of $3.92m.
June 30, 2026 cash was $6.96m, current assets $20.78m, current liabilities $21.20m, and accumulated deficit $38.97m.
H1 2026 physician-office revenue fell 93% YoY to $1.87m; hospital revenue was $12.08m following the BioTissue acquisition.
Management expects losses and negative operating cash flow over the next 12 months; auditors cited substantial doubt about continuing as a going concern.
Use of proceeds and capital allocation
No proceeds from selling-stockholder resales; cash exercise of all warrants could generate gross proceeds of ~$5.6m for working capital and general corporate purposes.
A separate Roth Principal Investments equity facility permits discretionary sales of up to $40m over as long as 36 months, subject to pricing, share-count, and other conditions; net proceeds are intended for working capital and general corporate purposes.
Up to $10m is owed to BioTissue after Catalyze received 510(k) clearance; the payment remained unpaid in the filing, and debt and equity financing were being pursued.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Biostem Technologies
- Acquisition-driven pivot to surgical biologics, Nasdaq uplisting, and 510(k) product launch set stage for growth.BSEM
H.C. Wainwright 28th Annual Global Investment Conference - Committed equity facility enables up to $40M in stock sales, but dilution and going concern risks remain.BSEMRegistration filing
- Diversified portfolio, hospital channel growth, and margin recovery drive regenerative medicine expansion.BSEMMicro-Cap Virtual Conference
- Expanding hospital market access and clinical portfolio drive growth and profitability.BSEMCompany presentation
- Poised for growth in the $1B+ wound care market with proven technology and expanding market access.BSEMConference presentation
- Q2 revenue up 29% sequentially to $7.9M, but liquidity risk remains with $10M payment due.BSEMQ2 2026
- Resale registration covers 3.57M shares amid ongoing losses and major market transition.BSEMRegistration filing
- IPO filing registers resale of shares after major acquisition; company faces liquidity risks.BSEMRegistration filing
- Record Q2 and H1 revenue, strong margins, and growth focus, but customer concentration risk remains.BSEMQ2 2024
Next Biostem Technologies earnings date
Q3 202612 Nov, 2026
Biostem Technologies
Next Biostem Technologies earnings date
Q3 202612 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
BioStem Technologies Inc. is a life sciences and regenerative medicine company that focuses on developing, manufacturing, and commercializing placental-derived allografts for advanced wound care. The company uses its proprietary BioRetain process to produce perinatal tissue allografts, preserving key biological properties that support tissue regeneration. BioStem’s products are used in a range of medical applications, including wound management and tissue repair. The company's portfolio includes products such as VENDAJE, VENDAJE AC, and AmnioWrap2. The company is headquartered in Pompano Beach, Florida, and its shares are listed on the OTC market.